echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The State Council has stated that hospitals shall not default on dealer payments.

    The State Council has stated that hospitals shall not default on dealer payments.

    • Last Update: 2020-08-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Finishing: Chocolate medics dream of paying back money every night... 1, the State Council: guarantee 30 days to pay back August 6, the State Council official website issued "small and medium-sized enterprises this money, the State Council said can not owe!" The article shows that the current stable economic fundamentals to help small and medium-sized enterprises through the difficult times, to ensure that small and medium-sized enterprises to pay this matter has been urgent.
    it is understood that the State Council recently issued the Regulations on the Protection of payment of small and medium-sized enterprises (hereinafter referred to as the Regulations), effective from September 1, 2020 (the end of the text with an illustration interpretation, as well as the size of enterprises self-test method).
    The Regulations clearly stipulate that organs and institutions purchasing goods, works and services from small and medium-sized enterprises shall make payments within 30 days from the date of delivery of goods, works and services, and if otherwise agreed in the contract, the payment period shall not exceed 60 days.
    at present, China's public hospitals or cancel the establishment of institutions, but still belong to the nature of institutions.
    Regulations also require organs, institutions and large enterprises not to require small and medium-sized enterprises to accept unreasonable payment terms, methods, conditions and liability for breach of contract and other transaction conditions, and not to default on the amount of goods, works and services owed to small and medium-sized enterprises.
    in China's armed enterprises, most of them are small and medium-sized enterprises.
    August 5, the State Drug Administration released the 2019 Annual Report on Drug Regulatory Statistics, showing that by the end of 2019, there were 18,000 medical device manufacturers nationwide, an increase of 1,000 from 2018.
    8232 enterprises can produce one type of products, 10033 enterprises can produce second-class products, and 1977 enterprises can produce three types of products.
    By the end of 2019, there were 593,000 medical device enterprises in the second and third categories, an increase of 82,000 compared to 2018, of which 347,000 were operating only second-class medical device products, only 69,000 were operating three types of medical device products, and 177,000 were operating second- and third-class medical device products.
    According to the Medical Device Blue Book: China Medical Device Industry Development Report (2019), more than 90% of China's medical device manufacturers are small and medium-sized enterprises, with an average annual income of 30 million to 40 million yuan.
    2, the country defaulted on more than 890 billion yuan on January 17 this year, according to the People's Daily, Vice Minister of Industry and Information Technology Xin Guobin said at a regular briefing on state policy held by the State Council Information Office, as of the end of December 2019, government departments at all levels and large state-owned enterprises have sorted out more than 890 billion yuan in arrears to small enterprises of private enterprises, at that time has paid off more than 660 billion yuan, about 75% of the liquidation progress.
    Xin Guobin said that although the remaining more than 200 billion yuan in arrears accounts accounted for only 25% of the accounts, but the task of settlement is more difficult.
    analysis of the remaining arrears this year shows that more than 80 per cent of the arrears were non-difference.
    Most of these arrears are old accounts, the causes are particularly complex, coupled with some local financial resources are relatively tight, some arrears of enterprise production and operation difficulties, so the later task of clearing the debt should be difficult to chew hard bones.
    To this end, the Regulations emphasize the prohibition of disguised arrears of payment, and stipulate that institutions, institutions and large enterprises using non-cash payment methods such as commercial bills of exchange to pay small and medium-sized enterprises, shall make a clear and reasonable agreement in the contract, shall not force small and medium-sized enterprises to accept commercial bills of exchange and other non-cash payment methods, and may not use commercial bills of exchange and other non-cash payment methods disguised to extend the payment period.
    in fact, in addition to this State Council issued a letter, in December 2019, the Ministry of Industry and Information Technology issued the "public consultation on the timely payment of small and medium-sized enterprises (draft for comments)" (hereinafter referred to as "draft for comments").
    also expressly requires that state organs, institutions and large enterprises shall not abuse their dominant position in transactions to force small and medium-sized enterprises to accept unreasonable payment terms, methods, conditions and liability for breach of contract.
    large enterprises abuse their dominant position in the market to force small and medium-sized enterprises to accept unreasonable payment terms or delay payments to small and medium-sized enterprises, the market supervision and administration department shall order them to make corrections and impose a fine of between 100,000 yuan and 500,000 yuan.
    similar to the Regulations, the Draft for Comments also shows that state organs, institutions and large enterprises that purchase goods, works and services from small and medium-sized enterprises shall pay within 30 days;
    inspection or acceptance as a condition of payment as stipulated in the contract, the above-mentioned period may be extended for a maximum of 30 days.
    the responsibility for late payment, the Opinions make it clear that state organs, institutions and large enterprises shall pay overdue interest if they delay payment of payments to small and medium-sized enterprises.
    3, the capital pressure of the armed enterprises or become larger in the current market situation, the return of the arms companies and capital pressure seems to have increased.
    July 25th, Dabo Medical announced that its repayment cycle was getting longer.
    It is understood that at the end of 2019, Dabo Medical Receivables book balance of 261 million yuan, bad debt preparation of 0.23 billion yuan, accounts receivable turnover days in the current reporting period increased from 85.41 days in 2018 to 249.71 days, the current period to recover or transfer back the bad debt reserve amount of 23.3086 million yuan.
    recent years, with the gradual implementation of the two-vote system of orthopaedic implantation supplies in some provinces, its sales model has gradually changed from distribution mode to distribution mode.
    and distribution model, distribution mode, distributors to the hospital sales because of better hospital credit, so the quality of accounts receivable is better, the risk of bad debts is lower, but the repayment cycle is also longer.
    Moremore, on June 1st, according to the official website of the Shanghai Stock Exchange, Ningbo Tianyi Medical Devices Co., Ltd. said in its newly released prospecto that after the implementation of the two-vote system, the company's repayments will not be affected, but the one-vote system will lead to changes in the company's repayment cycle.
    The above-mentioned arms companies said that if the future "one-vote system" in the field of medical device circulation widely strict implementation, the issuer will be directly settled with the health insurance fund, the issuer's sales settlement model will be from the first payment after the goods to the first purchase after the main, the repayment cycle or will be longer.
    Nanchang University also published a paper analysis, said that under the influence of the two-vote system, the competition between the pharmaceutical circulation industry is becoming more intense, the overall growth rate of the industry will slow down, the probability of financial risks in the pharmaceutical circulation industry will continue to improve.
    addition, the pharmaceutical and equipment industry due to large capital investment, long repayment cycle, so that most of the enterprise debt management.
    statistics, the industry's average asset-liability ratio is more than 70%, from 2013 to 2017, the average asset-liability ratio from 76.8% to 72.95 percent, but the return on assets has remained basically unchanged, stable at about 18.5%.
    the high asset-liability ratio of the circulating industry indicates that there are high financial risks in the industry, and stakeholders and relevant managers should pay sufficient attention to it.
    attachment:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.